Antimony Market to Reach USD 1.85 Billion by 2034 Amid China Export Uncertainty

The global antimony market was valued at $1.12B in 2025 and is projected to reach $1.85B by 2034, a 5.7% CAGR. China’s suspension of its US-specific export ban is scheduled to expire November 27, 2026; whether it is extended will affect US access, supply options and price risk, while broader Chinese export licensing remains in place. North America is projected to grow at a 5.96% CAGR through 2034, with US defense acquisition targets rising for FY2026 and non-China supply projects potentially improving options in 2027–2030.

Analysis

Antimony offers a policy-driven scarcity premium, but this release is a market-research forecast, not evidence of realized demand, pricing, or company earnings. The November 27, 2026 decision is the near-term catalyst: an extension could ease immediate US procurement anxiety without removing China’s licensing leverage; non-extension could tighten US availability, but the price response depends on inventories, licensing and substitution. The DLA target increase is not confirmation of awarded contracts or delivered volumes.

Potential beneficiaries are non-China suppliers and processors, including the mapped PPTA, UAMY, AMG and CAMB, as well as named supply alternatives such as Nyrstar’s Port Pirie operation. Benefits are not interchangeable: the article gives no company-level antimony output, contract coverage, costs or ramp schedules. In particular, Perpetua’s project is a 2027–30 supply possibility, not near-term replacement tonnage. Downstream solar-glass, flame-retardant and lead-acid battery users could face input-cost pressure, though pass-through and antimony’s share of product cost are unknown.

Over 1–3 months, track Beijing’s decision, US import availability, spot/contract prices and actual procurement awards. Over 6–18 months, permitting, financing and commissioning determine whether diversification constrains the scarcity premium. The contrarian point: a long-run market CAGR does not establish an imminent shortage, and the reported demand shares do not translate directly into listed-company earnings. A clear extension plus stable prices would unwind urgency; persistent licensing delays, rising prices and confirmed non-China deliveries would validate it.

Key Decisions for Investors

• Avoid treating the market-size forecast as an earnings catalyst. Before taking single-name exposure, verify each company’s antimony production or project timeline, realized pricing, customer contracts and contribution to consolidated revenue.
• Set a November 27 event alert rather than buying broad exposure ahead of the decision. If non-extension is followed by documented US supply disruption and rising prices, consider a small, defined-risk tactical position in the most directly exposed verified producer; do not assume PPTA’s development project supplies near-term volume.
• Monitor downstream sensitivity in solar-glass, flame-retardant and lead-acid battery names only if antimony prices rise materially and companies disclose limited pass-through. Falsify the cost-pressure thesis if prices remain stable or customer contracts absorb the increase.
• For the 2027–30 diversification thesis, track permitting, financing and production milestones at Perpetua and actual shipment continuity from Port Pirie. Delays or weak non-China output would support a longer scarcity premium; sustained deliveries and easing prices would argue against it.